Jonathan Rubin - 10 Sep 2025 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
SVP, Chief Medical Officer
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
10 Sep 2025
Net transactions value
$0
Form type
4
Filing time
12 Sep 2025, 16:07:11 UTC
Previous filing
05 Mar 2025
Next filing
26 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rubin Jonathan SVP, Chief Medical Officer C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE /s/ Timothy C. Dec, as attorney-in-fact 12 Sep 2025 0001836067

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SUPN Common Stock 9,980 10 Sep 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Performance Share Unit Award $0 +1,875 $0.000000 1,875 10 Sep 2025 Common Stock 1,875 $0.000000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes an aggregate of 345 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
F2 On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.